Fasting Metabolic Markers There was a nonsignificant trend toward increased fasting glucose in those receiving alpelisib (plasma glucose 84 ± 5 mg/dL after placebo vs. 93 ± 11 mg/dL after alpelisib; P adj = 0.10) ( Fig. 2 A ).
← all excerpts
Single Dose of Phosphatidylinositol 3-Kinase Inhibitor Alpelisib Induces Insulin Resistance in Healthy Adults: A Randomized Feasibility Study.
1
—
—